Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

02-10-2019 | Genitourinary cancers | Video | Article

Expert highlights: Genitourinary cancers at ESMO 2019

print
PRINT
insite
SEARCH

Axel Merseburger takes us through his top picks of the genitourinary cancer research reported at the ESMO Congress 2019, including updates on the TITAN and STAMPEDE prostate cancer trials, the SORCE trial in renal cell carcinoma, and the investigation of first-line enfortumab vedotin in bladder cancer (5:33).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read the transcript

print
PRINT
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

Related content

08-10-2019 | Castration-sensitive prostate cancer | News | Article

HRQoL data bolster positive survival findings from TITAN study

28-09-2019 | Prostate cancer | Conference coverage | News

STAMPEDE shows docetaxel benefit regardless of metastatic burden

30-09-2019 | Renal cell carcinoma | Video | Article

Researcher comment: TITAN-RCC findings show efficacy of tailored immunotherapy approach
Image Credits